Primary Sclerosing Cholangitis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Primary Sclerosing Cholangitis - Pipeline Review, H1 2019’, provides an overview of the Primary Sclerosing Cholangitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis

- The report reviews pipeline therapeutics for Primary Sclerosing Cholangitis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Primary Sclerosing Cholangitis therapeutics and enlists all their major and minor projects

- The report assesses Primary Sclerosing Cholangitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Primary Sclerosing Cholangitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acorda Therapeutics Inc

Albireo Pharma Inc

Allergan Plc

Conatus Pharmaceuticals Inc

Dr. Falk Pharma GmbH

Gilead Sciences Inc

Intercept Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Nyrada ...

Acorda Therapeutics Inc

Albireo Pharma Inc

Allergan Plc

Conatus Pharmaceuticals Inc

Dr. Falk Pharma GmbH

Gilead Sciences Inc

Intercept Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Nyrada Inc

Pliant Therapeutics Inc

Sancilio & Company Inc

Seres Therapeutics Inc

Shenzhen HighTide Biopharmaceutical Ltd

Sirnaomics Inc

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents

Introduction

Primary Sclerosing Cholangitis - Overview

Primary Sclerosing Cholangitis - Therapeutics Development

Primary Sclerosing Cholangitis - Therapeutics Assessment

Primary ...

Table of Contents

Table of Contents

Introduction

Primary Sclerosing Cholangitis - Overview

Primary Sclerosing Cholangitis - Therapeutics Development

Primary Sclerosing Cholangitis - Therapeutics Assessment

Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development

Primary Sclerosing Cholangitis - Drug Profiles

Primary Sclerosing Cholangitis - Dormant Projects

Primary Sclerosing Cholangitis - Discontinued Products

Primary Sclerosing Cholangitis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Primary Sclerosing Cholangitis, H1 2019

Number of Products under Development by Companies, H1 2019

Products under ...

List of Tables

Number of Products under Development for Primary Sclerosing Cholangitis, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Acorda Therapeutics Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Conatus Pharmaceuticals Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Nyrada Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Pliant Therapeutics Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Seres Therapeutics Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, H1 2019

Primary Sclerosing Cholangitis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Primary Sclerosing Cholangitis - Dormant Projects, H1 2019

Primary Sclerosing Cholangitis - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Primary Sclerosing Cholangitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Primary Sclerosing Cholangitis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports